StockData
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. (CMMB) stock

CMMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 5/30
$1.55−0.09 (-5.49%)

Close on Nov 18, 2026Market cap $11.15MP/E 1.1Yield –

Chemomab Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -$112.00M. The highest annual figure on record is -$4.64M in fiscal 2016.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$112.00M–
FY2024Dec 31, 2024-$103.00M–
FY2018Dec 31, 2018-$13.04M–
FY2017Dec 31, 2017-$9.39M–
FY2016Dec 31, 2016-$4.64M–

More Chemomab Therapeutics figures

See a number that looks wrong?